1 / 11

Łódź , march 2006 r.

Financial results 4Q 2005 r. Łódź , march 2006 r. We keep our promises. Net Profit (PLN m). 2005. +22,9%. 2004. PGF’s Net profit growth. Net Profit (PLN m).

nona
Download Presentation

Łódź , march 2006 r.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Financial results 4Q 2005 r. Łódź , march 2006 r. Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  2. We keep our promises Net Profit (PLN m) 2005 +22,9% 2004 Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  3. PGF’s Net profit growth Net Profit (PLN m) * According to IAS and International GAAP. According to polish law companies should use IAS and IGAAP from the beginning of 2005 Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  4. We keep our promises Net margin (%) ROE (%) The highest ROE among polish listed wholesalers * According to IAS and International GAAP Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  5. 2005 Achivements • The highest sales in history • The highest net profit in history • We have build the biggest pharmacies group operating under the same brand (DoZ- Dbam o Zdrowie) • We have finished main part of restructuring process of two companies acquired in 2004 Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  6. PGF vs other listed pharmaceutical wholesalers • The biggest marketing program in health care sector – more than 1 milion households, more than 800 pharmacies operating under DoZ brand • We offer our partners value-added services • PGF is very well prepared for further growth • The highest ROE among polish listed pharmaceutical wholesalers • The highest operating cash flow among polish listed pharmaceutical wholesalers • The only listed pharmaceutical wholesaler that pays dividend Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  7. Plans for 2006 • Increasing number of pharmacies operating under DoZ brand • Decreasing operating costs ratio • Decreasing net debt • Maintain high, two-digit, dynamics of net profit growth Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  8. Sales and operating costs IVQ 2004 * IVQ 2005 change y/y I-IVQ 2004 * I-IVQ 2005 change y/y Sales ( PLN m) Gross profit on sales ( PLN m) Gross margin on sales(%) 6,9% 3,2% -0,35 p.p. 8,0% +0,08 p.p. 940,0 99,4 10,58% 74,1 7,88% 7,3% 3,0% -0,43 p.p. 2,8% -0,33 p.p. 3 639,0 363,4 9,99% 288,0 7,91% 3 891,5 375,0 9,64% 311,1 7,99% 1 008,7 102,4 10,15% 76,1 7,55% Total operating costs Operating costs ratio (%) *Data comparable, according to IAS and International GAAP Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  9. 31.12.2004 * 31.12.2005 change y/y Working capital 502,4 422,0 47,1 39,6 3,7% -0,5% -1,5 dnia -2,9 dnia Stocks (PLN m) Short-term accounts receivables (PLN m) Stock rotation ratio (days) Short-term receivables rotation ratio (days) 484,3 423,9 48,6 42,5 I-IV Q 2004 * I-IVQ 2005 change y/y Cash flow Operating CF Investing CF Financing CF Total net CF 59,8 -157,8 108,3 10,4 75,4 -51,6 -28,8 -4,9 26,0 -67,3% *Data comparable, according to IAS and International GAAP Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  10. Shareholders’ equity and debt 31.12.2004 * 31.12.2005 change r/r Shareholders’ equity (PLN m) Total debt (PLN m) Cash and short term investments (PLN m) Net debt (PLN m) debt / equity debt / EBIDTA 187,0 358,1 43,6 314,5 1,68 3,90 211,6 379,2 38,6 340,6 1,61 3,73 13,2% 5,9% -11,3% 8,3% -4,3% -4,3% *Data comparable, according to IAS and International GAAP Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

  11. Profit and margins I-IVQ 2004 * I-IVQ 2005 change y/y IVQ 2004 * IVQ 2005 change y/y PLN m EBITDA EBIT Gross profit Net profit attributable to equity holders EBITDA margin EBIT margin Pre-tax margin Net margin 80,6 67,7 64,4 47,7 2,22% 1,86% 1,77% 1,31% 13,1% 9,9% 10,5% 9,2% +0,13 p.p +0,05 p.p. +0,06 p.p. +0,03 p.p. 91,2 74,4 71,1 52,1 2,34% 1,91% 1,83% 1,34% 11,0 10,5 10,1 6,5 1,17% 1,12% 1,07% 0,69% 31,1 26,6 24,5 16,7 3,09% 2,64% 2,43% 1,66% 183,1% 153,8% 142,5% 156,9% +1,11 p.p +1,52 p.p. +1,35 p.p. +0,96 p.p. *Data comparable, according to IAS and International GAAP Polska Grupa Farmaceutyczna S.A. • Łódź, march 2006

More Related